#162063

Anti-Anterior gradient 3 [AGR3.1]

Cat. #162063

Anti-Anterior gradient 3 [AGR3.1]

Cat. #: 162063

Sub-type: Primary antibody

Availability: 3-4 weeks

Target: Anterior gradient 3

Class: Monoclonal

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Moravian Biotechnology

Tool Details
Target Details
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Anterior gradient 3 [AGR3.1]
  • Clone: AGR3.1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.
  • Reactivity: Human
  • Host: Mouse
  • Description: Antibody created to detect the endogenous AGR3 protein in both cytosolic and membrane fractions of breast cancer cells (with higher affinity than the AGR3.2 antibody). Binding specificity: Human AGR3 protein. Epitope HETTDKNLS (determined using pepscan).
  • Immunogen: Purified human AGR3 protein
  • Isotype: IgG1 kappa
  • Production details: B cell donor: Splenocytes from mouse immunised with purified AGR3 protein, fusion partner: SP2

Target Details

  • Target: Anterior gradient 3
  • Molecular weight: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa.
  • Target background: AGR3 (Anterior Gradient 3) is a human homologue of the XAG-2 protein expressed in Xenopus laevis, which was identified in a study analyzing mRNA expression in ER-positive breast cancer-derived cell lines. The coding sequence of the AGR3 protein is located on the chromosome at position 7p21. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor ?)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers.
  • Epitope sequence: HETTDKNLS sequence of Anterior gradient 3

Handling

  • Format: Liquid